Skip to content
ClinCalc Pro
Menu
Vasoactive Intestinal Peptide (VIP) + Alpha-Adrenoceptor Antagonist (Intracavernosal Erectile Dysfunction) Pregnancy: Section 4.6: 'Not relevant. Invicorp is only indicated in men. No reproduction studies have been carried out on animals using a combination of aviptadil and phentolamine mesilate.'

Aviptadil with Phentolamine Mesilate

Brand names: Invicorp

Aviptadil with phentolamine mesilate is a combination intracavernosal injection used in the treatment of erectile dysfunction, typically when oral therapy is unsuitable or ineffective.

Adult dose

Dose: Adult males, symptomatic treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic or mixed aetiology: Invicorp 25 micrograms / 2 mg - one dose (one 0.35 ml ampoule) containing aviptadil 25 micrograms and phentolamine mesilate 2 mg, by direct intracavernosal injection. The injection should provide an erection satisfactory for sexual intercourse; the duration of the erection is recommended not to exceed one hour.
Route: Intracavernosal injection
Frequency: As needed; injection frequency should not exceed once daily or 3 times weekly
Strength and unit: SPC section 2 - '1 dose (ampoule 0.35 ml) contains 25 micrograms of aviptadil and 2 mg of phentolamine mesilate'; SPC section 4.2 heads the posology 'Invicorp 25 micrograms / 2 mg'. Only this single strength is covered; section 4.2 (as retrieved) prints no titration steps or alternative per-injection amounts, so none are written. The SPC prints a frequency limit, not a maximum dose. Must be done under sterile conditions. Usual injection site: along the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate the side of the penis and the injection site between injections. The initial injections must be administered by medically trained personnel; after proper training Invicorp may be injected at home. The ampoule can be brought to room temperature before use or used directly from the refrigerator. Regular patient monitoring (e.g. every 3 months) is recommended, particularly in the initial stages of self-injection therapy. Underlying treatable medical causes of erectile dysfunction should be diagnosed and treated before starting. Not suitable for concomitant use with other treatments of erectile dysfunction or erection-inducing drugs (sections 4.4, 4.6).

Dose adjustments

Renal

SPC section 4.2: no formal studies have been performed in patients with impaired renal function; no dose adjustment is printed.

Hepatic

SPC section 4.2: no formal studies have been performed in patients with impaired hepatic function; no dose adjustment is printed.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substances or to any of the excipients (section 4.3)
  • Men for whom sexual activity is not advisable or is contraindicated due to organic disease (section 4.3)
  • Conditions that might predispose to priapism, such as sickle cell anaemia or trait, multiple myeloma, or leukaemia (section 4.3)
  • Anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie's disease (section 4.3)
  • Penile implants (section 4.3)
  • Not recommended in children (section 4.2); indicated in adult males only (section 4.1)

Side effects

  • Approximately 10% of patients experience adverse reactions (section 4.8)
  • Common: flushing (often observed but rarely problematic) (section 4.8)
  • Uncommon: headache, dizziness, tachycardia, palpitations (section 4.8)
  • Rare: priapism, prolonged erection; penile nodules/fibrosis following multiple injections (section 4.8)
  • Very rare: myocardial infarction, angina pectoris (section 4.8)
  • Injection-site bruising, haematoma and pain post injection (section 4.8; the frequency columns for these are not reliably readable in the PDF text, so none is assigned)
  • Penile fibrosis (angulation, cavernosal fibrosis, fibrotic nodules, Peyronie's disease) may occur and may increase with duration of use (section 4.4)

Interactions

  • Use with caution with anticoagulants such as heparins and warfarin, including oral anticoagulants such as dabigatran, rivaroxaban or apixaban (section 4.5)
  • No clinical interaction observed with concomitant anti-hypertensive or other cardiovascular medication (section 4.5)
  • Other treatments for erectile dysfunction (e.g. sildenafil) or drugs that induce erection (e.g. papaverine) should not be used with Invicorp because of the potential for prolonged duration of erections (sections 4.4, 4.6)

Monitoring

  • Regular patient monitoring (e.g. every 3 months), particularly in the initial stages of self-injection therapy (section 4.2)
  • Regular follow-up with careful examination of the penis to detect signs of penile fibrosis or Peyronie's disease; discontinue if penile angulation, cavernosal fibrosis or Peyronie's disease develops (section 4.4)
  • Patients to report immediately any erection lasting a prolonged period such as 4 hours or longer; treatment of priapism should not be delayed more than 6 hours (section 4.4)
  • Caution in severe cardiovascular or cerebrovascular conditions; discontinue if tachycardia occurs (section 4.4)

Clinical monograph

How it works

Aviptadil (a vasoactive intestinal polypeptide analogue) and phentolamine (an alpha-adrenoceptor antagonist) together promote cavernosal smooth muscle relaxation and increased arterial inflow, producing an erection.

Prescribing in practice

  • Prolonged erection and priapism can occur and require prompt treatment to avoid permanent erectile tissue damage.
  • The first dose should be given under supervision so that the patient can be taught correct self-injection technique.
  • Avoid in conditions predisposing to priapism and in penile anatomical abnormalities or implants.

Monitoring

Monitor for prolonged erection, injection-site reactions and penile fibrosis with continued use.

Counselling the patient

  • Seek urgent medical help for any erection lasting longer than the time advised by your clinician.
  • Use correct aseptic self-injection technique and rotate the injection site as instructed.

Evidence & guidelines

Intracavernosal therapy for erectile dysfunction is an established second-line option supported by clinical use and the SPC.

Reference: NICE CKS Erectile dysfunction (2023); EAU Guidelines on Sexual and Reproductive Health (2024); Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.